Trouble reading this email? View it in your browser
European Federation of Pharmaceutical Industries and Associations EFPIA Newsletter 14 March 2024
      Healthcare innovation moves fast – so should the European regulatory system
 
 
By Sabine Atzor (Roche) and Alan Morrison (MSD)
 

What will the innovations of tomorrow look like and how can they be regulated effectively without delaying access?

This is a key question facing policymakers as they aim for EU competitiveness while ensuring patients get new technologies that address their needs. One of the most exciting ‒ and challenging ‒ features of today’s research landscape is the potential to tap into the combined power of advances in diagnostics, therapeutics and new data and digital tools, including artificial intelligence (AI), to create integrated healthcare solutions.

These solutions can address gaps in the patient journey and deliver better outcomes for patients with greater efficiency for health systems. (...)

Read more →
 
 
      News
 
  13 March 2024 Yes to EHDS, but not at any cost: EFPIA calls upon the EHDS trilogue negotiators to take sufficient...

EFPIA reiterates its call to the co-legislators to take sufficient time for critical examination of the EHDS draft regulation...

Read more →
 
 
 
  13 March 2024 EFPIA and Vaccines Europe statement on the revision of the EU variations framework

We consider these targeted changes to be encouraging steps towards a more efficient, streamlined framework which may...

Read more →
 
 
 
      Blogs
 
  12 March 2024 Reintegrating cancer patients into professional and social life

People with certain cancers are living longer, fuller lives. We must come together to support their return to work

Read more →
 
 
 
      Events
 
 
19 MAR 2024
  Regulatory Reliance Tools Unveiled: A Practical Guide by EMA Virtual event

Jointly organised by six industry partners.

Learn more →
 
 
 
16 APR 2024
  Rare Diseases Forum: Securing Europe’s competitiveness in R&D for people living with... Brussels

Join to address how and why innovation in tackling rare diseases can support the EU’s competitiveness agenda.

Learn more →
 
 
      Publications

The pharmaceutical industry shares concerns about the environmental impact of PFAS. However, PFAS is a broad non-specific term which does not inform whether a compound is harmful, and not all PFAS present the same risks to the environment or health. The potential impact of a Europe-wide ban on PFAS in pharmaceutical products, packaging and operations is significant. We need strategic planning and alternative approaches to avoid disruptions in patient care. Check our infographic and read more here.

 
 
      What we are reading
Calling for a comprehensive EU policy response to improve the cardiovascular health of European... 14 March 2024  (EACH) Read more →
Solving unmet needs with regulation at the pace of science and technology 13 March 2024  (The Parliament Magazine) Read more →
Poland gradually narrowing access gap for innovative cancer medicines 13 March 2024  (Euractiv) Read more →
STAKEHOLDER SURVEY: What should the EU's health priorities be? 12 March 2024  (The European Observatory) Read more →
    About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 36 national associations and 39 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

 
Tel: +32 (0)2 626 25 55
Communications@efpia.eu
▶ in
 
EFPIA 2026 All rights reserved  ·  Disclaimer  ·  Unsubscribe